Yangkai Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yangkai Xu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Lemin Zheng
The Institute of Cardiovascular Sciences, the Institute of Systems Biomedicine, School of Basic Medical Sciences, Health Science Center, Peking University, Beijing, China
2 shared publications Hongtu Cui
1 shared publication- Jie Chen
Peking University
1 shared publication - Jing Xue
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication - Kerry-Anne Rye
University of New South Wales
1 shared publication - Mingming Zhao
State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 19 September 2022
- Published by AccScience Publishing in Global Translational Medicine
- Vol. 1 (2) , 160
Succinate metabolism in cardiovascular diseases
Cardiovascular disease (CVD) refers to a class of diseases related to the heart or blood vessels that have high global incidence. Succinate is generally considered an important intermediate product of the tricarboxylic acid cycle. Recent studies have shown that succinate is related to the pathophysiology of CVD, such as atherosclerosis, acute aortic dissection, hypertension, myocardial ischemia-reperfusion injury, and heart failure. It may represent a potential target or biomarker for CVD. It has been demonstrated that succinate not only participates in various energy metabolic pathways but also plays an important role in various pathophysiological activities as a signaling molecule. Given the significance of metabolism in CVD, it is important to focus on the metabolic regulation mechanism of succinate in CVD. This review outlines the latest evidence pointing to the potential role of succinate in CVD, along with its mechanisms, and updates the current understanding on the role of succinate in CVD. Further studies may focus on identifying succinate, its receptor, and its downstream signaling molecules as new targets for the prevention and treatment of CVD.
- 19 September 2022
- Published by AccScience Publishing in Global Translational Medicine
- Vol. 1 (2) , 160
Open AccessSuccinate metabolism in cardiovascular diseases
Cardiovascular disease (CVD) refers to a class of diseases related to the heart or blood vessels that have high global incidence. Succinate is generally considered an important intermediate product of the tricarboxylic acid cycle. Recent studies have shown that succinate is related to the pathophysiology of CVD, such as atherosclerosis, acute aortic dissection, hypertension, myocardial ischemia-reperfusion injury, and heart failure. It may represent a potential target or biomarker for CVD. It has been demonstrated that succinate not only participates in various energy metabolic pathways but also plays an important role in various pathophysiological activities as a signaling molecule. Given the significance of metabolism in CVD, it is important to focus on the metabolic regulation mechanism of succinate in CVD. This review outlines the latest evidence pointing to the potential role of succinate in CVD, along with its mechanisms, and updates the current understanding on the role of succinate in CVD. Further studies may focus on identifying succinate, its receptor, and its downstream signaling molecules as new targets for the prevention and treatment of CVD.
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 1-11
HDL Structure
HDL has various protein components, including enzymes, complement components, apolipoproteins, protease inhibitors, etc. In addition to proteins, lipids are also a significant component of HDL. These components and their structure determine the function of HDL. HDL is heavily involved in the acute response phase, complement regulation phase, hemostasis phase, immune response phase, and protease inhibition phase. Among the apolipoproteins, the predominant component is Apo A-I, which confers various atherogenic activities to HDL. Apo A-II, Apo-C, Apo-D, Apo-F, Apo-H, Apo-J, and Apo-O, which can bind free fatty acids, regulate the activity of many proteins involved in HDL metabolism, inhibit lipid transfer, and control the endogenous coagulation cascade. A major functional component is the enzyme LCAT, which helps catalyze the conversion of cholesterol to plasma-based lipoproteins and then to cholesteryl esters. Another enzyme associated with HDL is human paraoxonase, calcium-, PON1-, PON2-, and PON3-dependent lactone enzyme with catalytic activity, including reversible binding to substrates. PAF-AH is a phospholipase with lipoprotein properties, and HDL and LDL particles are commonly bound to plasma PAF-AH for circulation. As for lipid components, PC is an essential phospholipid subclass and may be a biomarker for constitutive inflammation. Sphingolipids, such as sphingomyelin and ceramide, also play an indispensable role in HDL function. In different physiological and pathological stages and plasma environments, HDL can exhibit different structural features, such as discoid HDL and spherical rHDL. Keywords HDL Structure Apolipoprotein Metabolism
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 1-11
HDL Structure
HDL has various protein components, including enzymes, complement components, apolipoproteins, protease inhibitors, etc. In addition to proteins, lipids are also a significant component of HDL. These components and their structure determine the function of HDL. HDL is heavily involved in the acute response phase, complement regulation phase, hemostasis phase, immune response phase, and protease inhibition phase. Among the apolipoproteins, the predominant component is Apo A-I, which confers various atherogenic activities to HDL. Apo A-II, Apo-C, Apo-D, Apo-F, Apo-H, Apo-J, and Apo-O, which can bind free fatty acids, regulate the activity of many proteins involved in HDL metabolism, inhibit lipid transfer, and control the endogenous coagulation cascade. A major functional component is the enzyme LCAT, which helps catalyze the conversion of cholesterol to plasma-based lipoproteins and then to cholesteryl esters. Another enzyme associated with HDL is human paraoxonase, calcium-, PON1-, PON2-, and PON3-dependent lactone enzyme with catalytic activity, including reversible binding to substrates. PAF-AH is a phospholipase with lipoprotein properties, and HDL and LDL particles are commonly bound to plasma PAF-AH for circulation. As for lipid components, PC is an essential phospholipid subclass and may be a biomarker for constitutive inflammation. Sphingolipids, such as sphingomyelin and ceramide, also play an indispensable role in HDL function. In different physiological and pathological stages and plasma environments, HDL can exhibit different structural features, such as discoid HDL and spherical rHDL. Keywords HDL Structure Apolipoprotein Metabolism
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 27-47
HDL and Endothelial Function
Plasmid high-density lipoprotein (HDL) is a critical biomarker in predicting cardiovascular diseases. Endothelial cells are physically located in the intima of blood vessels, which directly contact with circulating substances. Numerous previous studies have demonstrated that HDL exert protective effects on maintaining endothelial integrity and enhance anti-inflammatory functions, etc. In this chapter, we introduced how HDL benefit endothelial functions. We summarized the function of HDL on endothelial cell, such as endothelial permeability, proliferation, migration, apoptosis, etc. In addition, we discussed the effects of HDL on classical endothelial functions, such as coagulation and vasodilation. Although HDL have huge effects on endothelial functions, lots of cardiovascular diseases such as atherosclerosis could not be fully prevented and treated. Thus, a further understanding of the relationship between HDL and endothelial cell is needed, which would create a potential therapeutic approach to cardiovascular diseases. Keywords HDL Endothelial cells Endothelial barrier integrity Endothelial function
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 27-47
HDL and Endothelial Function
Plasmid high-density lipoprotein (HDL) is a critical biomarker in predicting cardiovascular diseases. Endothelial cells are physically located in the intima of blood vessels, which directly contact with circulating substances. Numerous previous studies have demonstrated that HDL exert protective effects on maintaining endothelial integrity and enhance anti-inflammatory functions, etc. In this chapter, we introduced how HDL benefit endothelial functions. We summarized the function of HDL on endothelial cell, such as endothelial permeability, proliferation, migration, apoptosis, etc. In addition, we discussed the effects of HDL on classical endothelial functions, such as coagulation and vasodilation. Although HDL have huge effects on endothelial functions, lots of cardiovascular diseases such as atherosclerosis could not be fully prevented and treated. Thus, a further understanding of the relationship between HDL and endothelial cell is needed, which would create a potential therapeutic approach to cardiovascular diseases. Keywords HDL Endothelial cells Endothelial barrier integrity Endothelial function